CSL partners with Alentis Therapeutics to co-develop lixudebart, while Jiangsu Nhwa licenses a clinical-stage sleep disorder candidate to Somnivera.
|Articles|July 25, 2018
Novartis Partners with SHYFT
Advertisement
SHYFT Analytics announced that Novartis selected its Intelligent Platform for Life Sciences to support the commercialization of therapies in Europe.
Novartis will use the following SHYFT solutions:
- STRATA Data Platform to aggregate and manage a growing number of third party and proprietary commercial data sources
- LUMEN Insights Platform to deliver intuitively-designed analytics to drive the “next-best-actions” for commercial teams
Advertisement
Related to this article
How earlier signals of misconnection may help pharma identify trust breakdowns before they show up as lagging measures in adherence, initiation, engagement, and outcomes.
Why GLP-1s achieving bariatric surgery-level efficacy is the field's most surprising advancement of the past decade.
Foghorn Therapeutics and Eli Lilly discontinue their SMARCA2 degrader program, Novartis licenses Abogen's autoimmune mRNA therapy while AstraZeneca, Daiichi Sankyo, and Summit Therapeutics team up on a breast cancer combination trial, and Corxel's Bo Liang makes the case for oral GLP-1 therapies.
Foghorn Therapeutics and Eli Lilly are discontinuing their SMARCA2 degrader Fhd-909 after Phase I data fell short on efficacy.
Novartis licenses Abogen's mRNA-encoded CD19xCD3 T-cell engager, while AstraZeneca and Daiichi Sankyo partner with Summit Therapeutics.
CORXEL’s Dr. Bo Liang on why small molecule oral therapies will be the long-term winners in a GLP-1 market driven by consumer preference.
Regeneron and Sanofi expand their antibody alliance with four new drug candidates, FDA approves Camzyos for adolescents with obstructive hypertrophic cardiomyopathy, and Michael Abrams questions digital health's savings claims to employers.
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: Novartis & Abogen Enter Licensing and Option Agreement, AstraZeneca and Daiichi Sankyo Enter Clinical Collaboration with Summit Therapeutics
2
Foghorn Therapeutics & Eli Lilly Halt Fhd-909 Development Following Phase I Data
3
How a Shift Towards Oral Medications Impacts GLP-1s
4
The Next Chapter in Metabolic Drug Development
5